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Intestinal failure associated cholestasis
Background: Surgery for necrotizing enterocolitis (NEC) and spontaneous intestinal perforation (SIP) is often
complicated by intestinal failure (IF) and intestinal failure associated cholestasis (IFAC).
Objective: Assessment of incidence, predictors, and mortality associated with IFAC in surgically treated NEC and
SIP.
Methods: A retrospective observational study based on hospital records during 1986–2014 in the two largest
Finnish neonatal intensive care units was performed. IFAC was defined as conjugated bilirubin N34 μmol/l
(2.0 mg/dl) for ≥ two postoperative weeks while receiving parenteral nutrition (PN).
Results: In total 225 patients underwent surgery for NEC (n= 142; 63%) or SIP (n= 83; 37%). Included were 57
survivors with ≥two weeks PN. Sixty-five (42%) patients developed IFAC. Two-year survival with IFAC was 80%
andwithout IFAC 89% (p=0.13). Of the 65 patients with IFAC, all eight with unresolved IFAC died in comparison
to six of 57 (11%)whose IFAC resolved (p b 0.0001), while IFAC resolved in all survivors. Survival among patients
with resolved IFAC was 89% and with unresolved IFAC (n= 8) 0%, (p b 0.0001). IFAC lasted for median 83 (IQR
45–120) days and correlatedwith the duration of PN (R2=0.16, p= 0.03), delay of starting enteral feeds (R2=
0.12, p=0.05) and PN lipid emulsion (RR=1.0 (95%CI=1.0–1.1) (p=0.02). Inmultivariate logistic regression
analysis, IFAC development associated with septicemias and reoperations.
Conclusions: 42% of prematures who underwent surgery for NEC or SIP developed IFAC. Reoperations and septi-
cemias increased the risk of IFAC. None of the patients with unresolved IFAC survived, but IFAC did not increase
overall mortality.
Type of study: Retrospective prognosis study.
Level of evidence: Level II.
© 2018 Elsevier Inc. All rights reserved.Cholestasis is a common and severe complication in neonates who
undergo extensive intestinal surgery and receive parenteral nutrition
for long periods of time. Necrotizing enterocolitis (NEC) and spontane-
ous intestinal perforation (SIP) are themost common intestinal diseases
of premature infants. NEC or SIP occurs in as much as 2% of patients in
neonatal intensive care units (NICU) [1–4]. In patients with Bell stage
III NEC [5] or SIP, surgery is almost invariably required. Mortality in sur-
gically treated NEC remains high ranging from 30% to 50% [6–8]. Be-
cause of extensive loss of small intestine and impaired motility of
remaining intestine, surgery for NEC or SIP is accompaniedwith intesti-
nal failure (IF) in as many as 42% of patients [9,10], and long periods of
parenteral nutrition (PN) are required. In pediatric IF development of
cholestasis is a poor prognostic sign [11]. Even if intestinal failureelsinki, Finland.
naleena.Anttila@pshp.fi
hus.fi (M. Pakarinen),associated cholestasis (IFAC) resolves, significant liver fibrosis and
steatosis may persist years after surgery and weaning off PN [12].
In this retrospective observational study we assessed IFAC in patients
with surgically treated NEC or SIP in twomajor level III NICUs in Finland.
During the study period from 1986 to 2014 there were a total of 22,000
admissions in both NICUs. Main outcome measures were incidence of
IFAC, risk factors of IFAC development and effect of IFAC on mortality.
1. Methods
The Ethical Review Board approved this study. Data including oper-
ative details, duration of PN and septicemiaswith positive blood culture,
were collected from the hospital records. Included were premature
(gestation age b 37 weeks) neonates who underwent surgery owing
to acute deterioration caused by NEC (radiological signs consistent
with of Bell stage III) or SIP. NEC and SIP were differentiated according
to 1) preoperative diagnostics: SIP was characterized by intestinal per-
foration with free gas in plain x-ray, NEC occurred with or without
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surgery: in SIP there was a single perforation without or with a limited
(≤2 cm) length of ischemic intestine, in NEC therewas a significant seg-
ment of ischemic intestine with or without perforation and sometimes
several affected sites of intestine could be observed 3) supportive data
from pathologist's report of the resected intestine.
Patients with intestinal conditions inconsistent with NEC of SIP,
stricture after conservatively managed NEC, NEC related intestinal ne-
crosis in term or almost term (N37 weeks) babies with cardiac disease
or gastroschisis, were excluded.
In both centers (NICUA and NICUB) pediatric surgical services were
located in the same hospital building enabling prompt consultations
and surgerieswere performed inNICU. Soybeanoil based PN lipid emul-
sion (Intralipid®) was used in NICUA from 1986 to 1995 and in NICUB
from 1986 to 2007. NICUA used PN lipid emulsion containing 50:50
soy-bean oil and medium-chain triglyceride emulsions (Vasolipid®)
from 1996 to 2001. PN lipid emulsion containing 80% of olive oil and
20% soy-oil (Clinoleic®) was used in NICUA from 2001 on and in
NICUB from 2008 on. During the last years of the study period PN lipid
emulsion containing soybean oil, olive oil rich medium-chain triglycer-
ides and fish oil (SMOF)was used in a small number of patients. For rea-
sons of simplicity comparisons concerning PN lipid emulsions were
performed between emulsions based on soy-bean oil (Intralipid®)
and other PN emulsions (Vasolipid® and Clinoleic®, SMOF).
IFAC was defined by conjugated bilirubin N34 μmol/l (2.0 mg/dl) for
≥2 postoperative weeks while receiving PN only or PN with enteral nu-
trition. Bilirubin was measured on clinical indications including jaun-
dice on PN and estimated duration of PN and IF exceeding one week.
Measurements occurred at least once a week when bilirubin values
were rising, or once in two weeks when the values remained high or
began to sink.
Patients who died within two weeks after the first surgery or had PN
less than 14 days,were excluded from thefinal assessment. Survival afterTable 1




A (100) 61 (61
B (57) 31 (54
Era
1986–2000 (79) 53 (68
2001–2014 (78) 39 (50
NEC vs SIP
NEC (n = 98) 51 (52
SIP (n = 59) 41 (69
Birth weight, g 968 (76
Gestation age, weeks 27 (25
Age at first surgery, days 9(6–
Apgar score 1 min 5 (3–
10 min 7 (5–
Mechanical ventilation, weeks 3.0(1.0
Cerebral hemorrhage Grade I–II 16 (18
Grade III–IV 24 (26
Severe / moderate RDS 46(50
PDA, no therapy 43 (47
PDA, medical or surgical therapy 49 (53
Other significant heart disease 10 (11
Resection of small intestine % 10 (3–
PN lipid solution
soy oil based (n = 67) 43 (64
other (n = 90) 49 (54
Length of PN days 32(21
PN before surgery, days 2(0–
EN started after surgery, days 7(4–
Number of septicemias 1(0–
Survival 3 months 85 (92
2 years 84 (89surgery was assessed up to two years. Predictive factors for the develop-
ment of IF-associated cholestasiswere testedwith univariate Logistic Re-
gression. Test included birth weight (BW) and gestation age (GA),
treating center (NICUA, NICUB), gender, respiratory distress syndrome
(RDS), Apgar points, heart disease and patent ductus arteriosus, age at
first surgery, diagnosis (NEC vs SIP), relative loss (%) of gestation age-
adjusted length of the small intestine [13], type of operation (enteros-
tomy vs primary anastomosis), loss of ileocecal valve, any intestinal
reoperations excluding final closure of enterostomies, length of PN,
start of PN and enteral nutrition (EN) in relation to surgery, total number
of septicemias (= clinical septicemiawith positive blood culture) during
PN, early (1986–2000) vs late (2001–14) study period and soy-bean
based vs other PN lipid emulsion. Because the incidence of IFACmay de-
pend on the relative number of patients who survived two weeks after
surgery, we compared 2 week survival in early (1986–2000) (116 pa-
tients) and late (2001–2014) (109 patients) periods of the study as
well as periods with PN A (109 patients) and PN B (116 patients).
Statistical calculationsweremade with StatView 512 computer pro-
gram (Brain Power, Calabasas, CA). If not otherwise stated data are pre-
sented as medians with IQR (= interquartile range) or frequencies.
Continuous variables were compared with Mann–Whitney and
Kruskal–Wallis tests, nominal values with Fischer's Exact Test. Cumula-
tive survival was analyzed with Kaplan–Meier analysis. Predictors for
IFAC and for resolution of IFAC were analyzed with Cox proportional
hazard regression analysis, generating risk ratios with 95% confidence
interval. Numerical correlations with Simple Regression Test Statisti-
cally significant independent predictors were included in the multivar-
iate model; p-values below .05 were considered significant.
2. Results
In total 225 patients from 1986 to 2014 with NEC or SIP, 131 (58%)
from NICUA and 94 (42%) from NICUB, were assessed. Sixty-eightts 68 either with PN duration b14 days (n = 21) or death b14 days after surgery were
(n = 92) IFAC (n = 65)
%) 39 (39%) 0.5
%) 26 (46%)
%) 26 (32%) 0.03
%) 39 (50%)
%) 47 (48%) 0.04
%) 18 (31%)
0–1145) 760 (651–1056)* 0.004
–29) 26 (25–28) 0.19
15) 10 (7–20) 0.23
6) 5 (3–6) 0.84
8) 7 (5–8) 0.56
–5.0) 5.0(2.0–7.1)* 0.01
%) 14 (22%) 0.54
%) 11 (17%) 0.24
%) 33 (51%) 0.94
%) 36 (55%)
%) 29 (45%) 0.33
%) 6 (9%) 0.11







%) 59 (91%) 0.77
%) 52 (80%) 0.06
Table 2
Location of disease, loss of gestation age adjusted intestinal length (%), surgical manage-





Primary location of disease
Small intestine 80(92%) 60(87%) 0.43
Colon 12 (8%) 5 (13%)
Resection of small intestine (%)
(n = 140)
10 (3.2–24) 21 (8–51) 0.001
Resection of colon (%) (n = 17) 6.0 (3.0–12) 5.0 (4.2–5.0) 0.45
Type of first surgery
-resection and enterostomy 64 (70%) 45 (69%)
-resection and primary anastomosis 28 (30%) 16 (25%)
-drainage 0 4 (6%)a 0.20
Ileocecal valve resected (n = 35) 13(14%) 22 (63%) 0.006
Reoperations (patients reoperated)b 25 (27%) 43 (66%) b0.001
Reoperations (surgeries /patient) b 0 (0–1) 1(0–2) b0.001
Final technique after reoperations
-enterostomy (n = 123) 69 (75%) 54 (83%) 0.25
-primary anastomosis (n = 34) 23 (25%) 11 (17%)
a All patients with drain as primary surgery underwent a reoperation, i.e., enterostomy.
b Final enterostomy closure excluded.
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or had PN for less than 14 days (n= 21)were excluded. Twoweek sur-
vival in the period 1986–2000 was 76% and in 2001–2014 was 84%
(p = 0.15). The final assessment of IFAC included 157 (70%) of 225
patients.
IFAC developed in 65 (41%) of 157 patients. Of 34 patients who
remained with PN three months after surgery 26 (76%) developed
IFAC. IFAC manifested a median of 18(7–42) days after surgery. Before
resolution median duration of IFAC was 83(45–120) days. Independent
factors that correlated with the length of IFAC were the length of PN
(R2 = 0.16, p = 0.03), time to starting enteral feeds after surgery
(R2 = 0.12, p = 0.05) and use of other PN lipid emulsion (RR = 1.04,
95% CI = 1.01–1.07) (p = 0.02).
The incidence of the IFAC increased from 32% during the early study
period (1986–2000) (79 patients) to 50% during the late period
(2001–14) (78 patients) (p=0.04). Clinical data of patientswhodevel-
oped and did not develop IFAC are outlined in Table 1. Statistically sig-
nificant differences between patients who did or did not develop IFAC
included the intestinal disease (NEC), birth weight, time in mechanical
ventilation, loss of small intestine, length of PN (= from start of PN to
total weaning), start of PN before surgery, start of enteral nutrition
after surgery and number of septicemias.
Surgical procedures are outlined in Table 2. Surgical techniqueswere
similar in patients who developed or did not develop IFAC. Excluding
the final enterostomy closures, reoperations were performed to a total
of 78 (50%) patients. Of the 124 patients with enterostomy, 114 (75%)
survived to undergo final enterostomy closure, which occurred after a
median of 9.5 (5.7–14) weeks after the first surgery.Table 3
Predictive factors for the development of IFAC in logistic regression analysis.
Univariate analysis
RR (95% CI)
Era (2001–2014) 2.0 (1.1–3.9)
Birth weight 0.999 (0.998–1.0)
% of small intestine resected 1.024 (1.009–1.04)
Septicemias (number of) 1.8 (1.3–2.6)
Reoperations (number of surgeries) 5.5 (2.8–11)
NEC (vs SIP) 2.1 (1.1–4.1)
Ileocecal valve resected 3.1(1.4–6.7)
Duration of PN (PN 1.007 (1.002–1.012)
Start of PN at or after surgery 2.0 (1.0–3.9)
Time to start of EN after surgery 1.012 (1.0–1.024)Factors that in Logistic Regression Analysis predisposed to IFAC are
outlined in Table 3. The strongest predisposing factors were number
of septicemias and number of reoperations (Table 3).
Two-year survival among the 157 patients was 85 (95% CI= 80–91)
%. From the early (1986–2000) to the late (2001–14) era survival im-
proved from 80 (95% CI = 71–89) % to 91 (95% CI = 85–97) % (p =
0.04).
Ten (11%) of 92 patients without IFAC and fourteen (22%) of 65 pa-
tients with IFAC died (p = 0.07); the median age at death was 41
(28–140) days and 140 (48–221) days, respectively (p = 0.04). Effect
of IFAC on 3-month and 2-year survival was not statistically significant.
Three-month cumulative survival in patients without IFAC (n = 92)
was 92 (95% CI = 84–96%) % and with IFAC (n = 65) 91 (95% CI =
84–98%) %, and two-year survival was 89 (95% CI = 83–96) % and 80
(95% CI = 70–90) % respectively, Log-Rank Mantel–Cox, p = 0.13. Sur-
vival with IFAC during early era (1986–2000) (73; 95% CI = 56–90%)
and during late era (2001–14) (85; 95% CI = 73–96%) was comparable
(p = 0.28).
2.1. Resolution of IFAC
IFAC resolved in 57 and did not resolve in eight patients. Comparison
of clinical data between patients with resolved and unresolved IFAC is
shown in Table 4. Predisposing factors for nonresolution of IFAC were
assessed with Logistic Regression Analysis, but none were found. Of
eight patients with unresolved IFAC none survived 2 years. Causes of
death were recurred multiorgan failure (n = 4), septicemia (n = 2)
and liver failure (n = 2). In two patients multiorgan failure was trig-
gered by recurrent intestinal disease. Laboratory tests including serum
conjugated and unconjugated bilirubin, bile acids, gamma-glutamyl
transferase and transaminases of the eight patients with unresolved
IFAC showed no signs of beginning resolution of IFAC. None of patients
with unresolved IFACwere suitable candidates for liver transplantation.
2.2. Parenteral nutrition
Overall median duration of PN was 42(24–74) days. At one month
53/150 (35%) and at three months 110/144 (76%) of the survivors
were weaned from PN. Median duration of PN in patients with IFAC
was 70 (36–150) days and significantly longer than 32 (21–49) days
in patients without IFAC (p b 0.001). Of 134 patients who survived
two years (IFAC n = 52, no IFAC n = 82), 133 were weaned from PN.
Of 23 patients who did not survive two years five died weaned from
PN and 18 on PN at the median age of 182 (151–550) and 48
(36–140) days, respectively (p= 0.02). Among patients in whom dura-
tion of PN exceeded 90 days (n = 33), two-year survival in patients
with soy oil based PN (n = 11) was 46% (95% CI = 16–75) compared
with 91% (95% CI = 79–102) in patients with other lipid emulsions
(n = 22), Log Rank Mantel Cox, p = 0.0045. Enteral nutrition (EN)
could be started median 9 (5–21) days after surgery. Start of EN inMultivariate analysis




0.001 1.6 (1.0–2.3) 0.05







Comparison of clinical data between patients with resolved and nonresolved IFAC.
IFAC resolved IFAC not resolved
57 8
NICU
A (n = 39) 35/39 (90%) 4/39 (10%) 0.70
B (n = 26) 22/26 (85%) 4726 (15%)
Era
1986–2000 (n = 26) 22/26 (85%) 4/26 (15%) 0.70
2001–2014 (n = 39) 35/39 (90%) 4/39 (10%)
NEC: SIP
NEC (n = 47) 41/47 (87%) 6/47 (13%) 0.99
SIP (n = 18) 16/18 (89%) 2/18 (11%)
Birth weight, g 830 (651–1085) 688 (628–710) 0.12
Gestation age, weeks 26 + 2 (24 + 5–28 + 2) 24 + 5(24 + 1–26 + 5) 0.15
Age at first surgery, days 10(6–21) 9 (6–16) 0.68
Apgar score 1 min 5 (3–6) 4 (3–5) 0.10
10 min 7 (6–8) 5 (4–7) 0.04
Mechanical ventilation, weeks 5.0(2.0–7.0) 6.0(4.2–7.5) 0.59
Cerebral hemorrhage Grade I–II 13 (23%) 1 (12%) 0.70
III–IV 9 (16%) 2 (25%)
Severe / moderate RDS 27(48%) 6 (75%) 0.26
PDA, no therapy 31 (54%) 5 (63%) 0.78
PDA, medical therapy 13 (23%) 1 (12%)
PDA, surgical therapy 13 (23%) 2 (25%)
Other significant heart disease 9 (16%) 1(12%) 0.75
PN lipid emulsion
soy oil based (n = 24) 20 (35%) 4 (50%) 0.45
other (n = 41) 37 (65%) 4 (50%
Length of PN days 64 (36–150) 47 (26–69) 0.28
PN before surgery, days 1 (0–3) 1 (0–4) 0.90
EN started after surgery, days 15 (8–39) 22 (8–33) 0.68
Number of septicemias 1 (1–2) 2 (1–3) 0.64
Resection of small intestine % 20 (7.0–49) 14 (7.5–44) 0.85
Ileocecal valve
intact (n = 43) 39 (68%) 4 (50%) 0.42
resected (n = 22) 18 (32%) 4 (50%)
Reoperations (patients reoperated) 38 (67%) 5 (63%) 1.0
Reoperations (surgeries/patient) 1 (0–2) 1 (0–2) 0.91
Survival 3 months 56 (98%) 3 (38%) p b 0.001
2 years 52 (91%) 0 (0%) p b 0.001
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IFAC 8 (4–14) days after surgery.
3. Discussion
In the present study we analyzed the incidence, effect on overall
mortality and risk factors of IFAC in prematureswhounderwent surgery
for NEC or SIP over a 29-year period in the two largest Finnish NICUs.
The main results of the present study were: 1) the overall incidence of
IFAC was high (41%); 2) incidence of IFAC increased on the latter
study period to 50%; 3) the strongest predisposing factors for IFAC
were septicemias and reoperations; 4) mortality in patients with IFAC
was 20%, and all patients with unresolved IFAC died.
The increase of the incidence of IFAC may be associated with the
trend toward higher overall two-week survival at the latter study pe-
riod. Higher two-week survival in turn has increased the amount of pa-
tients at risk of IFAC. According to a recent systematic review the
incidence of pediatric cholestasis and liver disease associated with PN
and IF has not changed from 1970s to 2000s [14].
In the series of Elfvin et al. the overall incidence of IFAC among 153
surgical NEC patients was 33%, and 49% of patients had IF lasting over
42 days and 16% over 90 days, respectively [15]. In the present study
the overall incidence of IFAC was 41% with the percentage of patients
with IF (ie. the percentage dependent on PN) at 90 days slightly higher
(24%) than in the series of Elfin et al. [15].
Mortality of IFAC did not change during the early and late study pe-
riods. In our series consisting of premature neonates, mortalityassociatedwith IFACwas 20%. However, none of our patientswith unre-
solved IFAC survived. IFAC, however, did not cause a statistically signif-
icant increase in overall mortality. In prematures with extremely low
birth weight IFAC associated with intestinal disease has been reported
to result in disastrous 77% mortality [16].
Themost important risk factors for thedevelopment of IFACwere in-
testinal reoperations and septicemias. The indications of intestinal
reoperations after surgery for NEC and SIP include recurrent NEC, anas-
tomotic complications and intestinal obstruction. Reoperations delay
the recovery of intestinal motility and administration of EN andmay re-
sult to further reduction of small intestine and prolonged PN. Septice-
mias from PN catheter infections and intestinal bacterial translocation
are very common amongNEC patients with PN [17]. The association be-
tween septicemias and IFAC has been also reported by other studies
[15,18]. In concordance with two previous studies by Duro D. et al.
and Elfvin A. et al. [9,15], we found no association between gestational
age and IFAC. In the present study, recovery from IF and resolution of
IFAC benefited from the fact that small intestinal loss was less than
25% in more than 50% of patients and since majority of the patients
were operated on at a low gestation age, compensatory growth of
small intestinewas to be expected. Thusmajority of the survivors even-
tually had enough small intestine and were weaned PN. Contrary to the
study by Duro et al. [9] we did not find preoperative PN a risk factor for
IFAC. This is probably because the duration of preoperative PN in our pa-
tients was short compared with the study by Duro et al. We found that
birth weight, relative loss of small intestine, loss of ileocecal valve,
length of PN, start of EN and NEC remained significant factors in
464 K. Karila et al. / Journal of Pediatric Surgery 54 (2019) 460–464univariate logistic regression analysis but not inmultivariate analysis. In
our series IFAC manifested median 18 days after surgery, that is, at a
time when duration of PN was less than 50% of the median total dura-
tion of PN of 42 days. At the time of themanifestation of IFAC enteral nu-
trition had been started only in half of the affected patients. The early
manifestation of IFAC may explain why neither the total length of PN,
relative loss of small intestine nor the loss of ileocecal valve predicted
IFAC in multivariable logistic regression analysis. IFAC in surgical NEC
and SIP may have a multifactorial etiology that includes severity of the
intestinal disease, long duration of PN and recurring septicemia, to-
gether with prematurity and immaturity of hepatic and intestinal func-
tion. Surgery itself is not a prerequisite for IFAC. Yan et al. [18] reported
5% incidence of cholestasis among 1074 nonsurgical premature neo-
nates with prolonged (over 43 days) PN, and male sex and septicemia
were found as the main risk factors for of cholestasis.
The adoption of alternative lipid emulsions has not been shown to
change the incidence and outcome of IFAC [19]. With a retrospective de-
sign the present study was not well suited for comparison of lipid emul-
sions. We could not show that a change from soy-oil based to olive oil
based PN emulsion had any effect on the development, duration or resolu-
tion of IFAC. Inpatientswith PNmore than90dayswe found that two-year
survival in patients with soy oil based PN emulsion was lower than in pa-
tients with other PN emulsions. However, the significance of this finding is
uncertain because other factors than PN may have affected mortality.
The weakness of the present study was its retrospective design.
Under the study period from 1986 to 2014 neonatal care has undergone
many changes such as ventilation techniques,medication and parenteral
nutrition that unavoidably confound the final assessment of the results.
Surgical techniques have not changedmuch except that during the latter
study period drainage of the abdomenwas introduced as an initial stabi-
lizing measure. In the present series all patients who survived drainage
eventually underwent a definite open surgical procedure. Moreover we
could not include proper data of enteral nutrition (e.g. starting times, vol-
umes), energy delivered by parenteral and enteral nutrition and the con-
sistence of the nutrients in an individual patient in our statistical
assessment. Total and conjugated bilirubin values were the most consis-
tently serially measured blood tests among our patients whereas serial
measurements of blood tests for liver function were unavailable in
many patients and thus not presented.
The present study included in a national scale a substantial number
of successive prematures who underwent surgery for NEC and SIP in
two NICUs. The incidence of IFAC has increased but remains similar
than reported incidence in contemporary literature. From our data we
could not pinpoint the reason for the increased incidence of IFAC. The
present study and other previous studies [16] support the fact that
IFAC increases the risk of death. In patients who died with unresolved
IFAC we could not assess the exact mechanism of death but we believe
that unresolved IFAC with no signs of resolution is associated with sig-
nificant metabolic derangement and impeded hepatic function and is
a major contributor to death.
The present patient series is collected froma longperiod of timedur-
ingwhichmanagement of neonates has evolved significantly. However,the incidence and surgical management of NEC and SIP in our series
have not changed much from 1986 to 2014. It seems that the major
hit in development of IFAC occurs early with the serious intestinal dis-
ease in a premature whereas after surgery the possibilities to prevent
IFAC still remain limited. Comparing old patientmaterial with new pro-
vides at least an insight in the changing risk of IFAC; with new neonatal
treatment modalities, new PN emulsions, and the gathered knowledge
of IF and IFAC, the incidence of IFAC has not decreased but increased.
Even with its limitations, the present study provides an actual insight
into the clinical course of NEC and SIP patients with IFAC.
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